CASP3 and melanoma: Treatment of melanoma cells with a nanomolar concentration of mTOR kinase inhibitors such as everolimus or Torkinib showed statistically significant effects on caspase 3 activation and apoptosis, but this result was lower compared to other mTOR kinase inhibitors used.